A prefilled research pen containing high-purity Retatrutide solution, supplied exclusively for laboratory research
A recent University College London research estimates that 1.6 million adults in England, Wales and Scotland used GLP-1s, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight.
The monthly check-in appointments allow the patient and provider to adjust the dosage or their diet and exercise plan as necessary
However, differences in sociodemographic profile and comorbidities were present, such as higher incomes and educational level of GLP-1 RAs users compared with SGLT-2 inhibitor users and DPP-4 inhibitor users suggesting selection bias in prescription
They can also cause rare and occasionally severe side effects including acute pancreatitis and acute gallbladder diseases as well as intestinal obstruction and gastroparesis
The drug is also known by its active ingredients generic name, semaglutide